Open-Label Memantine in Fragile X Syndrome

Autor/inn/en	Erickson, Craig A.; Mullett, Jennifer E.; McDougle, Christopher J.
Titel	Open-Label Memantine in Fragile X Syndrome
Quelle	In: Journal of Autism and Developmental Disorders, 39 (2009) 12, S.1629-1635 (7 Seiten) PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	0162-3257
DOI	10.1007/s10803-009-0807-3
Schlagwörter	Mental Retardation; Rating Scales; Patients; Genetic Disorders; Physiology; Drug Therapy; Symptoms (Individual Disorders); Pervasive Developmental Disorders; Behavior Modification; Pharmacology + Suchen Sie Ihr Suchwort? Geistige Behinderung; Rating-Skala; Patient; Physiologie; Psychiatrische Symptomatik; Behaviour modification; Verhaltensänderung; Arzneikunde
Abstract	Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed. Six patients received memantine over a mean 34.7 weeks of treatment. Four of 6 (67%) patients showed global clinical benefit on ratings with the CGI-I. Symptom specific rating scales, however, showed no statistically significant improvement. Two patient developed treatment-limiting irritability on memantine. Memantine was modestly effective in several patients with FXS. Further systematic study is warranted. (As Provided).
Anmerkungen	Springer. 233 Spring Street, New York, NY 10013. Tel: 800-777-4643; Tel: 212-460-1500; Fax: 212-348-4505; e-mail: service-ny@springer.com; Web site: http://www.springerlink.com
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10